Results 121 to 130 of about 22,335 (252)

The role of mitochondrial dynamics in metabolic dysfunction-associated steatotic liver disease. [PDF]

Front Med (Lausanne)
Yang N, Hao Y.
europepmc   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

Alimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella   +2 more
wiley   +1 more source

Maternal Dyslipidaemia Aggravates Offspring Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Basic Clin Pharmacol Toxicol
Pedersen K, Buhl SF, Højgaard-Jensen C, Lykkesfeldt J, Tveden-Nyborg P.   +4 more
europepmc   +1 more source

Phosphatidylethanol in the Management of Steatotic Liver Disease

Baggrund: Steatotisk leversygdom (SLD) dækker over et spektrum af tilstande med ophobning af lipider i hepatocytter, herunder metabolisk dysfunktion-associeret steatotisk leversygdom (MASLD), alkoholrelateret leversygdom (ALD) og den nyligt definerede fænotype metabolisk og alkohol-relateret leversygdom (MetALD).
openaire   +2 more sources

Re‐Evaluating the Comparison of Four Different Ultrasound Elastography Techniques for Diagnosing Advanced Fibrosis

Portal Hypertension &Cirrhosis, EarlyView.
Zain Ul Abedeen, Iqra Alam, Muhammad Atif, Sameer Saleem   +3 more
wiley   +1 more source

Real‐world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T‐cell therapy

British Journal of Haematology, EarlyView.
In this real‐world cohort of 231 patients receiving chimeric antigen receptor (CAR) T‐cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12‐month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71–1.94).
Julius Hollnberger, Tim Richardson, Philipp Gödel, Joshua Leutiger, Jan Christoph Schumacher, Sophie Schiestel, Benedict Allhoff, Christof Scheid, Udo Holtick, Christoph Neumann‐Haefelin, Gabriel Allo, Philipp Kasper   +11 more
wiley   +1 more source

Prevalence and Correlates of Steatotic Liver Disease Among People With HIV in Uganda. [PDF]

Open Forum Infect Dis
Bibangambah P, Acan M, Ghoshhajra B, Erem G, Nassanga R, Ochieng A, Thondapu V, Lu MT, Randhawa M, Takigami A, Reynolds Z, Atwiine F, Tindimwebwa E, Gilbert RF, Hoepner SS, Passell E, Sagar S, Tong Y, Ntusi NAB, Hahn J, Gaziano T, Longenecker CT, Tsai AC, Manne-Goehler JM, Asiimwe S, Okello S, Siedner MJ.   +26 more
europepmc   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

A comparison of plasma Tsukushi in adolescents with and without metabolic dysfunction-associated steatotic liver disease. [PDF]

Physiol Rep
McNeese SA, Maltz SA, Kim Y, Teague AM, Palle SK, Friedman JE, Short KR.   +6 more
europepmc   +1 more source

Transcriptomic and metabolomic analyses reveal that lobeglitazone ameliorates hepatic steatosis in rats concurrent with regulation of mitochondrial pyruvate metabolism

British Journal of Pharmacology, EarlyView.
Background and Purpose Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2 diabetes mellitus.
Hyekyung Yang, Su Young Son, Youngmi Song, Hyewon Choi, In‐Gu Do, Choong Hwan Lee, Cheol‐Young Park   +6 more
wiley   +1 more source